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TNP-470 inhibits collateralization to complement the
anti-tumour effect of hepatic artery ligation
T Mugitani, H Taniguchi, A Takada, A Yamaguchi, M Masuyama, M Hoshima and T Takahashi
First Department of Surgery, Kyoto Prefectural University of Medicine
Summary We examined hepatic artery ligation combined with an angiogenesis inhibitor, TNP-470, in the treatment of VX2 tumour inoculated
into the liver of rabbits. Effects on tumour growth were correlated with arterial collateral development in this system. Three treatment methods
were compared: (1) the left hepatic artery was ligated at the liver hilum (ligation group); (2) TNP-470 (40 mg per body) was infused
continuously for 7 days via the common hepatic artery (TNP group); (3) the left hepatic artery was ligated and TNP-470 was infused
continuously for 7 days via the common hepatic artery (ligation + TNP group). These treatments were started 12-14 days after tumour
inoculation. The day of initiating treatment was defined as day 0. Although there were no significant differences in tumour volume among the
three treated groups on day 7 aftertreatment, tumour volumes in the ligation + TNP group were significantly smallerthan in the ligation group
and the TNP group on day 14 aftertreatment. The vasculature and arterial collaterals around the tumour were demonstrated by the perfusion
of a silicon rubber solution, Microfil. In the ligation + TNP group, the new microvasculature around the tumour decreased compared with the
ligation group. The TNP-470 inhibition of microvascular proliferation may limit the development of collaterals that communicate with new
feeding arteries. These results suggest that transarterial embolization combined with TNP-470 may enhance the anti-tumour effect of
transarterial embolization alone in the treatment of liver tumours.
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Hepatic artery ligation (HAL) and transarterial embolization
(TAE) have been useful for the treatment of inoperable liver
tumours (Nilsson and Zettergren, 1967; Fortner et al, 1973;
Chamsangavej et al, 1983; Yamada et al, 1983). The rationale for
this treatment approach is that liver tumours receive their blood
supply almost exclusively from the hepatic artery (Breedies and
Young, 1954). The rapid development of arterial collaterals after
these treatments reduces this therapeutic effect (Fortner et al,
1973; Pettersson, 1975; Burgener, 1980; Yamada et al, 1983) and,
thus, inhibition of the development of arterial collaterals may be
important in enhancing the therapeutic efficacy of these treat-
ments. Doppman (1978) reported that peripheral hepatic artery
occlusion was more effective than proximal occlusion in
preventing the development of collaterals. Hepatic artery
embolization with gelfoam powder or collagen embolic agent has
achieved good results in an experimental model (Cho et al, 1983,
1989). Long-term decollateralization has been achieved by
shielding the liver surface with silicon rubber sheeting in hepato-
cellular carcinoma patients (Sasaki et al, 1990). New embolic
agents, such as degradable starch microspheres or autologous
blood clots, have been used for inhibition of collaterals and
repeated TAE (Gunji et al, 1992; Taguchi et al, 1992).
TNP-470 selectively inhibits DNA synthesis in endothelial
cells, thus producing an anti-tumour effect by inhibiting the angio-
genesis required for tumour growth (Ingber et al, 1990; Kusaka et
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al, 1991; Kamei et al, 1992; Yamaoka et al, 1993). This suppres-
sion of angiogenesis suggests that TNP-470 may also inhibit the
development ofcollaterals after arterial occlusion by HAL or TAE
and may possibly result in stronger anti-tumour effects. In this
study, we usedthe VX2 tumours inoculated into the liverofrabbits
to examine the ability of TNP-470 to enhance the therapeutic
effect ofHAL.
MATERIALS AND METHODS
Animals and experimental tumours
Japanese white rabbits (2.5-3.0 kg) were used for this study. VX2
carcinoma cells were maintained in the spleens of rabbits. In the
second week after inoculation into the spleen, VX2 tumours were
isolated from the spleen under sterile conditions, broken into fine
pieces and suspended in Hanks' balanced salt solution. Afterfiltra-
tion, this cell suspension was used as an experimental sample.
Implantation of VX2 tumour cells in the liver
Under general anaesthesia with intravenous sodium pentobarbital
(30 mg kg-'), laparotomy was performed through a mid-line
abdominal incision. A total of 1.0 x 106 cells (0.25 ml of suspen-
sion containing 4.0 x 106 VX2 cells ml-') was injected directly
beneath the liver surface at the left side ofthe median hepatic lobe.
Twelve to 14 days after tumour cells inoculation, laparotomy was
again performed with intravenous anaesthesia. Treatment was
initiated (day 0) ifdiscrete tumours were seen on the liver surface.
These VX2 tumours measured 10.2 ± 0.7 mm (mean ± 95% confi-
dence interval) in diameter. There was no significant difference
among the four groups in pretreatment tumour size, and no corre-
lation between tumour size and animal body weight.
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Figure 1 The anti-tumour effect of hepatic artery ligation (HAL). Tumour
volumes in the HAL group were significantly smaller than those in the control
group on days 7 and 14 after treatment (*P < 0.05). Vertical lines are 95%
confidence intervals
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Figure 2 The anti-tumour effect of TNP-470 administration. Tumour
volumes in the TNP group were significantly smaller than those in the control
group on days 7 and 14 after treatment. Vertical lines are 95% confidence
intervals
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Figure 3 Comparison of the anti-tumour effect among the treated groups.
On day 7, no significant difference was observed among the HAL, TNP and
HAL+TNP groups. On day 14, tumour volumes in the HAL+TNP group were
significantly smaller than those in the HAL and TNP groups. Tumour volume
did not decrease from the pretreatment size in any group. Vertical lines are
95% confidence intervals. NS, not significant
Treatment
VX2 tumours grown on the left side ofthe median lobe ofthe liver
are fed primarily from the left hepatic artery, and consequently
ligation ofthe left hepatic artery can interrupt the blood supply of
this tumour.
HAL group (12 rabbits)
The hepatic artery was gently exposed at the hepatoduodenal
ligament. The left hepatic artery was ligated with a 4-0 non-
absorbable suture at the liver hilum.
TNPgroup (11 rabbits)
The angiogenesis inhibitor TNP-470[0-(chloroacetylcarbonyl)
fumagilol] was obtained from Takeda Chemical Industries, Osaka,
Japan. A total of40 mg ofTNP-470 was continuously infused for
7 days through a polyethylene catheter (Intramedic Polyethylene
Tubing, PE60) into the common hepatic artery via the left gastric
artery. TNP-470 was continuously infused for 7 days with a mini-
osmotic pump (Alzet model 2ML1, Alza, CA, USA). This pump
has a 2-ml capacity and can infuse at a constant rate (10 ul h-1) for
7 days.
HAL+TNPgroup (12 rabbits)
After ligation ofthe left hepatic artery at the liver hilum, 40 mg of
TNP-470 was continuously infused for 7 days into the common
hepatic artery through a polyethylene catheter.
Controlgroup (11 rabbits)
Distilled water (2 ml) was infused continuously for 7 days with a
mini-osmotic pump through a polyethylene catheter into the
common hepatic artery via the left gastric artery.
Evaluation of the anti-tumour effect
Tumour size was the product ofthe lengths ofthe major and minor
axes measured with callipers. The size ofeach tumour on the liver
surface was measured immediately before treatment (day 0).
Seven days after treatment, halfofthe rabbits in each group under-
went laparotomy to determine tumour size. The remaining rabbits
were evaluated on day 14. We evaluated the anti-tumour effect as
the tumour volume, which was calculated as follows: tumour
volume (mm3) = 0.5 x a x b2, where a is the length of the major
axis and b is the length ofthe minor axis measured with callipers.
Evaluation of the inhibition of arterial collateralization
The arterial vasculature was evaluated macroscopically in the HAL
and HAL+TNP groups. The vasculature and arterial collaterals
around the tumour were demonstrated by the perfusion ofa silicon
rubber solution (Microfil, Canton Bio-Medical Products, Boulder,
CO, USA) into the arterial circulation of the liver. Immediately
before being killed, 500 units ofheparin were administrated intra-
venously. Under open laparotomy the celiac artery was exposed,
and the splenic artery and arterial branches to the gastrointestinal
tract were occluded. Microfil MV-112 (white) was injected into the
celiac artery. After curing of the silicon rubber, the liver was
removed and underwent a clearing procedure. The specimens were
immersed in increasing concentrations ofethyl alcohol, 25-100%,
and finally in a solution of methyl salicylate. The specimens were
then examined visually, and the arterial vasculature filled with
Microfil was evaluated under a stereoscope.
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Figure 5 Schematic of the proposed mechanism of action of TNP-470.
TNP-470 inhibited the proliferation of new microvascular channels that
generally occur after hepatic artery ligation and consequently limited the
development of arterial collaterals
C
Figure 4 Peritumoral arterial vasculature filled with Microfil (magnification x
6.6). (A) Pretreatment. (B) Thin, twisted and serrated new vessels are noted
surrounding the tumour in the HAL group. (C) Microvasculature proliferation
is decreased in the region surrounding the tumour in the HAL+TNP group
Liver function tests
Serum alanine aminotransferase (ALT) and aspartate aminotrans-
ferase (AST) concentrations were determined before treatment
(day 0) and on day 3, day 7 and day 14.
Statistical analysis
Statistical analysis used the unpaired t-test or the ANOVA; a P
value < 0.05 was considered to be significant.
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Figure 6 The effect of treatment on transaminase concentrations. Serum
ALT concentrations on day 3 in the HAL and HAL+TNP groups were
significantly higher than those in the control group (*P< 0.05). There were no
significant differences on day 3 between the HAL and the HAL+TNP groups.
Transaminase concentrations in the HAL and the HAL+TNP groups were the
same on days 7 and 14. Vertical lines are one side of the 95% confidence
intervals
RESULTS
Comparison of anti-tumour effects
No significant difference in tumour volume on day 0 was observed
in the four groups. Tumour volumes in the HAL and TNP groups
were significantly decreased compared with the control group on
days 7 and 14 after treatment (Figures 1 and 2). No significant
differences in tumour volumes were observed among the HAL
group, TNP group and HAL+TNP group on day 7 (Figure 3).
HAL+TNP treatment reduced tumour growth, as tumour volumes
on day 14 were significantly smaller than those in either the HAL
or TNP groups. However, tumour volume did not decrease from
the pretreatment size even in HAL+TNP.
Inhibition of arterial collateralization as demonstrated
with Microfil (Figure 4)
Before treatment, limited vascularity was evident adjacent to the
tumour. In the HAL group, there was evident peritumoral vascular
proliferation demonstrated with Microfil. These microvessels were
ofthin calibre, twisted and serrated. In the HAL+TNP group, there
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was decreased peritumoral vascular proliferation compared with
the HAL group.
Liver function
Serum ALT concentrations on day 3 after treatment were higher in
the HAL and HAL+TNP groups than in the control group. There
was no significant difference on day 3 between the HAL group and
the HAL+TNP group. By days 7 and 14, the ALT concentrations
in the HAL and HAL+TNP groups did not differ from the control
group. ALT concentrations in the TNP group never differed from
the control group (Figure 6). The serum AST concentration paral-
leled the ALT concentration (data not shown).
DISCUSSION
TNP-470 is a synthetic analogue of fumagillin, a natural product
ofAspergillusfumigatus. Kusaka et al (1991) have reported that a
broad range of TNP-470 concentrations selectively inhibit
endothelial proliferation with a subsequent anti-tumour effect.
Daily and intermittent injection ofTNP-470 produces anti-tumour
effects against various tumours in mice (Ingber et al, 1990), and it
has also been reported that TNP-470 was able to prevent
micrometastasis by suppression of angiogenesis (Tanaka et al,
1995a and b; Konno et al, 1996). Tanaka et al (1995a) have
reported that intra-arterial administration of TNP-470 blocked
liver metastasis formation more effectively than intraportal or
systemic administration in a rabbit model.
Here, TNP-470 suppressed tumour growth but did not reduce
tumour volume (Figure 2). TNP-470 exerts its anti-tumour effect
primarily by acting on the tumour neovasculature and conse-
quently does not reduce tumour size as do many other anti-cancer
drugs (Ingber et al, 1990). After TNP-470 administration was
completed, the tumours regrew to a larger size with a blood supply
via the pre-existing feeding artery and probably also new prolifer-
ation of tumour vessels. These results are similar to those of
previous investigators (Ingber et al, 1990; Kamei et al, 1992;
Yamaoka et al, 1993).
The anti-tumour effect ofhepatic artery ligation was temporary,
probably because the tumour can derive additional blood supply
from arterial collaterals and the portal vein (Figure 1). Several
investigators have reported similar findings (Fortner et al, 1973;
Pettersson, 1975; Burgener, 1980; Yamada et al, 1983).
The anti-tumour effect ofHAL+TNP on day 14 was significantly
more effective than eitherTNP orHAL alone (Figure 3). After liga-
tion of the hepatic artery, new microvascular channels developed
from other arteries (Figure 4 and 5). These proliferating vascular
channels could communicate with new feeding arteries that are thus
regarded as arterial collaterals. The right subphrenic artery, which
is frequently developed after TAE of the hepatic artery in HCC
patients, is one of these collaterals. It appears in our study that
TNP-470 inhibited the proliferation of these new microvascular
channels and consequently inhibited the development of multiple
arterial collaterals (Figure 5). TNP-470 may be particularly effec-
tive in inhibiting the extrahepatic collaterals that have been classi-
fied by Charnsangavej et al (1982). Inhibition of the extrahepatic
collaterals may make it possible to perform TAE repeatedly.
Tumour volume was not reduced in the HAL+TNP group. This
may reflect continuing portal blood supply to the tumour.
We expected that transaminases would be higher in the
HAL+TNP group because the inhibition of collateral formation
after hepatic artery ligation would further decrease liverperfusion.
However, transaminase concentrations in the HAL+TNP and HAL
groups were the same. This may be explained by liver perfusion
from the portal vein and pre-existing intrahepatic arterial collat-
erals that were unaffected by TNP-470.
Although the treatment of choice for liver tumours is surgical
resection, many cases are inoperable because oftumour extension
and accompanying advanced cirrhosis (Okuda et al, 1985; The
Liver Cancer Study Group of Japan, 1987). Transarterial
embolization has been performed using gelatin sponge particles as
an embolic agent for patients with unresectable liver tumours.
However, the embolic effect is often limited in duration and the
development ofcollaterals is often observed. Some embolic mate-
rials can archive a permanent embolic effect. Therefore, inhibiting
collaterals is important in improving the effectiveness ofTAE. Our
results suggest that TAE combined with TNP-470 can inhibit
collateralization after TAE and improve the anti-tumour effect
compared with TAE alone. In this study, TNP-470 was adminis-
tered for 7 days only. We expect that longer administration of
TNP-470 may be more effective, and studies ofextended duration
are needed.
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